New Onset Diabetes After Transplantation
Conditions
Interventions
Intervention arm:Patients in the Sitagliptin group orally took the first 100mg of Sitagliptin two hours before transplantation.
Control arm:The control group received routine treatments, and the postoperative blood glucose monitoring and insulin therapy regimens were the same as in the experimental group
Sponsors
the First Affiliated Hospital, Zhejiang University College of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.First-time kidney transplant recipient; 2. At least one high-risk factor for new-onset diabetes after transplantation (NODAT), including age = 40 years, BMI = 24 kg/m2, smoking, and a history of diabetes; 3.Receiving standard triple immunosuppressive medications that include mycophenolate mofetil or mycophenolic sodium, tacrolimus and steroids
Exclusion criteria
Exclusion criteria: 1. Patients with a diagnosis of diabetes prior to kidney transplantation, or receiving anti-diabetic medications 2. Patients with a history of transplantation 3. Patients receiving more than one organ transplant. 4. Patients with HCV infection 5. Patients with a history of pancreatitis 6. Patients with a history of angioedema 7.Legal and behavioral capacity limitations 8.Researchers consider it inappropriate to include in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of NODAT at 1 year after kidney transplantation; | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of NODAT at 6 months after kidney transplantation;A1c level and pancreatic ß-cell function at 3, 6, and 12 months after transplantation;graft and patients survival at 3, 6, and 12 months after transplantation; | — |
Countries
China
Contacts
Public ContactJianyong Wu
the First Affiliated Hospital, Zhejiang University College of Medicine
Outcome results
None listed